.png){kind=logo}
Stock image for illustration purposes only - book cover, edition or condition may vary.
Bortezomib in the Treatment of Multiple Myeloma
N/A
€ 127.97
FREE Delivery in Ireland
Description for Bortezomib in the Treatment of Multiple Myeloma
Hardback. Multiple Myeloma (MM) is the second most-common blood cancer. Bortezomib is a promising anticancer-drug targeting the proteasome. This monograph on bortezomib is a valuable source of information for researchers and clinicians from oncology and pharmacology. Series: Milestones in Drug Therapy. Num Pages: 188 pages, biography. BIC Classification: MJCL2; MJF; MMG. Category: (P) Professional & Vocational. Dimension: 243 x 158 x 13. Weight in Grams: 416.
Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent the degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon the suppression of proapoptotic pathways. This monograph on bortezomib ... Read more
Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent the degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon the suppression of proapoptotic pathways. This monograph on bortezomib ... Read more
Product Details
Format
Hardback
Publication date
2010
Publisher
Birkhauser Verlag AG Switzerland
Number of pages
188
Condition
New
Series
Milestones in Drug Therapy
Number of Pages
180
Place of Publication
Basel, Switzerland
ISBN
9783764389475
SKU
V9783764389475
Shipping Time
Usually ships in 15 to 20 working days
Ref
99-15
Reviews for Bortezomib in the Treatment of Multiple Myeloma